3M's $7.35 billion PFAS deal is a $5.8 billion charge, and $1 billion of it isn't due until 2028

3M agreed to a pre-tax, nominal $7.35 billion over nine years to settle personal injury claims over firefighting foam made with PFAS, the "forever chemicals," according to the company's Form 8-K on SEC EDGAR. It was announced after the close on Tuesday. Shares hit an 8-1/2-year high on Wednesday, up about 9.8% to $194.37 in the afternoon, Reuters reported.

Two numbers, and why they differ

The headline $7.35 billion is the sum of payments spread to 2034. The accounting charge is smaller: 3M says it will book a pre-tax charge of about $5.8 billion in the fourth quarter, the present value of those payments. The $1.55 billion gap is time. Money paid in 2030 is worth less than money paid today. 3M says the charge is a special item and does not change its 2026 guidance.

The number behind the number: when the cash leaves

We went to the payment schedule filed as an exhibit to the 8-K. The maximum amounts, by date:

Source: Exhibit 11 (Payment Schedule) to 3M's 8-K. The pieces add to $7.35 billion (our arithmetic).

So 3M pays $50 million in 2026 and nothing in 2027. The first big check, $1.045 billion, is dated January 15, 2028 or 30 days after termination rights lapse, whichever is later. 3M's release says about 20% of payments fall in the final two years, timed to its other legacy settlements. Everything except the initial $50 million is contingent on neither side exercising its termination rights.

What is still conditional

The deal only works if enough claimants join. To take part, a plaintiff must release all PFAS-related personal injury claims. 3M's 8-K says the actual amount, terms and dates depend on participation thresholds, and that 3M can terminate if participation falls short. Chief legal affairs officer Kevin Rhodes told investors on the Wednesday call that 3M does not expect that to happen, per Reuters.

The settlement covers about 99% of current personal injury claims inside and outside the federal multidistrict litigation in South Carolina, with roughly 115,000 to 120,000 eligible plaintiffs, according to the release. Spread across them, $7.35 billion works out to roughly $61,000 to $64,000 a head (our arithmetic). That is a ceiling for illustration only: it includes the reserve for future claims, and the schedule does not set individual awards or legal fees. Claims by people who decline to join are not released. Judge Richard Gergel stayed the personal injury cases against 3M on Wednesday, Reuters reported.

Why the market liked it

UBS analyst Amit Mehrotra wrote that investors had expected a settlement of about $10 billion and that this one removes a "meaningful overhang," Reuters said. Compare the $7.35 billion with that expectation and the present-value charge with the cash timing, and the reaction is easier to read: a smaller, later and more certain bill. The release also says the claims relate mainly to PFAS compounds 3M announced in 2000 it would phase out, and that it stopped making PFAS globally by the end of 2025. 3M does not admit liability.

Who else should read the schedule

Any business that makes, buys or uses products containing PFAS has watched this docket, and 3M's earlier deals show the pattern: the company resolved claims from US public water suppliers in 2023 and more recently settled with the State of New Jersey, per its release. A manufacturer, a municipal fire department or an airport authority is not a party here, and nothing in the filing speaks to their exposure. What the filing does show is how a large defendant prices a mass tort: a headline number, a smaller accounting charge, and cash that lands years later.

What to watch: the participation count that triggers or ends the deal, the 3M fourth-quarter report where the $5.8 billion charge is booked, and the next court order in Charleston.

Sources: 3M Form 8-K, filed Nov. 4, 2026, with Exhibit 99.1 and the payment schedule; Reuters via Investing.com, Nov. 4, 2026. Share price as of the afternoon of Nov. 4. This is market information, not investment advice.